Induced Angiogenesis by Genic Therapy With VEGF165 in Advanced Ischemic Cardiomyopathy - Historical Controlled Trial

Instituto de Cardiologia do Rio Grande do Sul2 个研究点分布在 1 个国家目标入组 20 人开始时间: 2007年11月1日最近更新: 2008年10月15日

适应症

试验速览

阶段: 2 期
发起方
入组人数: 20
试验地点: 2
主要终点: Clinical finds

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Human Vascular Endothelial Grown Factor 165 (hVEGF165) administration is promising therapy induces a new vessels, arterioles and capillaries in regions whose revascularization surgery is not possible by direct or by percutaneous angioplasty. This study aims to evaluate the clinical effects and safety of gene therapy with hVEGF165 in patients with advanced coronary artery disease.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: — 至 75 Years（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Diagnosis coronary artery disease and symptomatic, despite optimal pharmacologic therapy
•Left ventricular dysfunction - left ventricular ejection fraction between 60% and 25% by echocardiogram
•Non-conventional revascularization, as seen by cineangiocardiography, attested by interventional cardiologist and cardiac surgeon
•Age below 75 years
•Absence of neoplasm

排除标准

未提供

结局指标

主要结局

Clinical finds

时间窗: eighteen months

次要结局

未报告次要终点

研究者

发起方

Instituto de Cardiologia do Rio Grande do Sul

申办方类型

Other

研究点 (2)

Loading locations...

相似试验

已完成

2 期

Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled TrialCoronary Artery Disease

NCT00620217National Institute of Cardiology, Warsaw, Poland52

撤回

1 期

Stem Cell Mobilization and VEGF Gene Transfer for Heart FailureIschemic Congestive Heart Failure (CHF)

NCT00279539Losordo, Douglas, M.D.

Unknown

2 期

NOGA Angiogenesis Revascularization Therapy: Evaluation by RadioNuclide Imaging - The Northern TrialMyocardial Ischemia

NCT00143585Unity Health Toronto120

已完成

1 期

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD TrialNeovascular Age-related Macular DegenerationWet Age-related Macular Degeneration

NCT03066258REGENXBIO Inc.42

Unknown

1 期

Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's PhenomenonSecondary Raynaud's Phenomenon

NCT02356809Human Stem Cell Institute, Russia30